Tyrosine Kinase Inhibitors in the Treatment of Metastasised Renal …
Among these therapies, the tyrosine kinase inhibitors (TKI) sorafenib and sunitinib were the first novel therapies approved for advanced RCC in Europe in 2006. Since then, many more TKIs have been introduced, but guideline recommendations of when to use them have also changed significantly since the introduction of immunotherapeutic agents (IO).
LRRK2 reduces the sensitivity to TKI and PD-1 blockade in
2025年3月22日 · Tyrosine kinase inhibitor (TKI) and immune checkpoint inhibitor (ICI) combination therapy is emerging as a major therapeutic strategy for advanced clear cell renal cell carcinoma (ccRCC). To ...
Immunotherapy Strategies After Immune Checkpoint Inhibitor …
2 天之前 · First-line treatment in metastatic renal cell carcinoma (mRCC) consists of an anti−PD-1 antibody administered in combination with either a CTLA-4 inhibitor or an oral vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor (TKI). 3-6 Additionally, adjuvant treatment with a PD-1 inhibitor has shown benefits in disease-free ...
Reviewing RCC Treatment Choices After Progression With IO/TKI
1 天前 · During a live event, Benjamin Garmezy, MD, discussed treatment options in renal cell carcinoma including IO/TKI combinations plus VEGF selectivity. Decrease or stabilization in metastatic lesions noted on follow-up imaging . He tolerated therapy well, with 1 interruption due to hypothyroidism on ...
Long-Term Data on IO/IO in RCC Shows Intriguing Results for …
1 天前 · It was the only dual immunotherapy (IO) trial in the front line, compared with 3 other regimens combining IO with tyrosine kinase inhibitor (TKI). It had 3 primary end points of overall response rate, progression-free survival (PFS), and overall survival (OS) focused on the patients with intermediate or high risk by International Metastatic RCC ...
Activity of lenvatinib-based therapy in previously treated patients ...
3 天之前 · Lenvatinib is a potential treatment after immunotherapy and TKI in refractory RCC. ABSTRACT. Background and Objective. Lenvatinib’s activity after immune checkpoint inhibitors (ICI) combination therapy in renal cell carcinoma (RCC) remains unknown. We aimed to describe the real-world outcomes of patients with metastatic RCC (mRCC) treated ...
Tyrosine kinase inhibitors and immunotherapy combinations in renal …
The treatment landscape of metastatic renal cell carcinoma (mRCC) has been transformed with the advent of antiangiogenics, notably tyrosine kinase inhibitors (TKIs) targeting vascular endothelial growth factor receptor (VEGFR), and immune checkpoint inhibitors (ICIs).
晚期肾透明细胞癌一线靶向治疗的优化选择中国专家共识（2022）
2022年5月19日 · 一项回顾性队列研究对接受tki治疗的晚期rcc 患者数据进行分析，评估6个相关基因突变状态（bap1、pbrm1、tp53、tert、kdm5c 和setd2）与肿瘤特异性结局之间的相关性，结果提示∶bap1、pbrm1、tp53 基因对晚期rcc的pfs和os有独立的预测价值。
Phosphorylation of MET Is Upregulated in Metastatic Sites of Renal …
1 天前 · In the treatment of metastatic RCC (mRCC), cabozantinib, a potent TKI targeting VEGFR and MET, has demonstrated an acceptable therapeutic effect . In the previous study, we evaluated the expression of MET and matriptase in the primary tumor and bone metastasis of RCC by using immunohistochemistry (IHC) . A higher expression of both molecules ...
Temporary cessation versus continued TKI therapy for RCC
2023年3月15日 · Tyrosine kinase inhibitor (TKI) treatment showed improved overall survival (OS) in patients with advanced or metastatic renal cell carcinoma (RCC).